Two subtypes of human bladder cancer, non-invasive papillary and muscle-invasive cancer, develop through independent pathologic and molecular pathways. Remarkably, invasive bladder cancer driven by active Stat3 was predominantly comprised of stem cells, which were characterized by cytokeratin 14 (CK14) staining and enhanced tumor sphere-forming ability. Active Stat3 was also demonstrated to localize to the nucleus of human invasive bladder cancers that were primarily composed of CK14+ stem cells. Together, our findings demonstrate that Stat3-induced stem cell expansion plays a critical role in the unique clinical progression of invasive bladder cancer through the CIS pathway.
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Introduction
Bladder cancer is the fifth most common cancer with 69,250 new cases annually in the United States. Urothelial carcinoma (UC) represents approximately 90% of bladder cancers, which arise from an epithelial origin. Two subtypes of bladder UCs exist: noninvasive papillary and muscle-invasive cancer. Evidence supports that these two subtypes develop through their own independent pathologic and molecular pathways, although certain overlap does exist (1) (2) (3) (4) . The vast majority of muscle-invasive cancers arise de novo from carcinoma in situ (CIS) without prior clinical progression through noninvasive papillary lesions (2, 4) . Muscle-invasive bladder cancer is clinically unfavorable with only a 5-year overall survival of 48-67% even after radical cystectomy (removal of entire bladder) for localized disease (5) .
Several signaling pathways, such as p53, pRB, PTEN and their downstream interacting proteins, have been described in mediating the development of invasive bladder cancer (6) (7) (8) (9) . For instance, TP53 mutation and RB inactivation is common in human bladder CIS (7, 8) and invasive cancer (6) , and were shown to be associated with poor prognosis (10, 11) . However, mouse model carrying urothelial-specific deletions of p53 and pRB only produced late-onset hyperplasia and low-grade noninvasive papillary bladder tumors (12) . Exposure of these urothelial-specific p53/pRB deficient mice to subcarcinogenic dose of the carcinogen, N-Butyl-N-(4-Hydroxybutyl)nitrosamine (BBN), led to 50% incidence of invasive bladder cancer, while single knock out mice of p53 or pRB did not develop invasive cancer in response to BBN (12) . Independently, lack of PTEN protein in human bladder cancer is shown to associate with poor outcome, and mouse urothelial-specific deletions of PTEN and p53 via an adeno-Cre delivery system to the bladder induces invasive cancer development (9) . Despite the current understanding of signaling pathways and mouse models for invasive bladder cancer, a mouse model representing the unique clinical progression of Ͷ invasive bladder cancer directly from CIS, without prior pathological appearance as noninvasive papillary tumor, is lacking. In the current study, we describe a novel mouse model that targets an active dimerized form of Signal transducer and activator of transcription 3 (Stat3) to the basal cells of bladder epithelium (urothelium). When Stat3 is constitutively active, the carcinogen BBN induced rapid progression of urothelial progenitor cells to atypical CIS formation and subsequent muscle-invasive cancer. This mouse model implicates a role for Stat3 in predisposing urothelial cells toward de novo CIS formation and invasive cancer development, which closely resembles the clinical pathogenesis of human invasive bladder cancer.
Materials and Methods
K5.Stat3 transgenic mice and Nitrosamine (BBN) treatment protocol.
K5.Stat3 transgenic mice were characterized as previously described (13) . Adult transgenic mice and wild-type littermates at 6-8 weeks of age were treated with 0.05% BBN in drinking water for 12 weeks, followed by regular drinking water. Mice were sacrificed at 1wk (n=4), 2wk (n=4), 4wk (n=4), 6wk (n=4), 13wk (n=4) and 20wk (n=42) after first BBN treatment. Mouse bladders were either fixed in 10% formalin and paraffin embedded for histological analyses or freshly dissociated for in vitro tumor-sphere forming assay.
Immunostaining and western blotting. Tumor sections were analyzed following standard H&E procedures or immunohistochemical analysis protocols (DAKO) (14) . Nikon microscopy system and NIS Elements software were used for imaging and semi- ͷ Tumor-sphere forming assay. Bladder tumors were enzymatically dissociated into single cell suspension as previously described (14) and their ability to generate sphere-forming stem cell colonies was analyzed in an in vitro assay as previously described (15) . In brief, viable single cell suspension of tumor cells were resuspended in 1:1 ratio of serum-free Keratinocyte Growth Media (Gibco/Invitrogen) and Growth Factor Reduced Matrigel TM (BD Biosciences, 356231). Tumor spheres formation were assayed 12 days after first plated.
Animal care and patient materials. All animal procedures were approved under protocol AN-5529 and all patient materials were approved under IRB protocol H-26809.
Results and Discussion
Urothelial characterization of Stat3 transgenic mice.
Stat3 is a latent transcription factor that normally resides in the cytoplasm. Upon growth factor/cytokine receptor or non-receptor tyrosine kinase-mediated activation, Stat3 rapidly translocates into the nucleus where it binds to consensus promoter region and activates target gene transcription (16) . The association of Stat3 to human invasive bladder cancer and poor survival has been reported (14, 17) . However, its biological role in de novo bladder tumorigenesis has not been fully explored. We previously reported the generation of transgenic mice overexpressing a dimerized form of active invasive bladder cancer. However, due to the limitation of the current model, it is impossible to trace the fate of these early lesions from wild-type mice and specifically pinpoint which pathological pathway followed during tumor progression. 
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Association of nuclear Stat3 localization with CK14+ tumor cells in human cancer patient.
To examine the human relevance of these bladder tumor results from mice, which implicate a role of Stat3 in invasive progression, we analyzed 8 early-stage (6 pTa LG, 2 CAN-11-3195 ͳʹ Ta HG) and 8 advanced stage human bladder cancers (1 TIS, 2 pT2, 5 pT3) (Supplemental Table 1 ). In early-stage bladder tumors, we observed 37.5% (3 of 8) of which express nuclear active Stat3, while 100% (8 of 8) of higher-stage bladder cancer expressed nuclear active Stat3 (Supplemental Table 1 
